Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with Zaynich™ (Zidebactam/Cefepime, WCK 5222)
Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with Zaynich™ (Zidebactam/Cefepime, WCK 5222)
Wockhardt’s Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves highest – ever efficacy meeting superiority in a global, pivotal, registration – enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate
Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem – Resistant Gram – Negative Pathogens
Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves over 97% Efficacy in Clinical Study for serious infections caused by Meropenem – Resistant Gram – Negative Pathogens
